Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The clinical success of biologics is often hindered by a lack of safe, targeted delivery systems. SiVEC Biotechnologies aims to change this with its groundbreaking BactPac platform.
By detecting and targeting myeloid-dependent immune suppression, Bectas Therapeutics is on a mission to realize the full potential of cancer immunotherapies.
Bio-Sourcing is developing innovative solutions that combine cutting-edge gene-editing and nuclear-transfer technologies to up-scale the production of biopharmaceuticals while lowering carbon emissions and costs.
PROVIREX is developing first-in-class advanced therapies that may offer the chance of a cure for people with life-threatening persistent viral infections.
Aleta Biotherapeutics is using its novel technology platform to develop bespoke, multi-antigen-targeting biologics for a diverse range of indications, including B-cell cancers and solid tumors, improving outcomes in patient populations with high unmet need.
The need to get novel biologic modalities to the right place effectively and efficiently is highlighted in major recent deals around drug delivery platforms.
Current guidelines recommend transdermal delivery of testosterone for post-menopausal women seeking treatment for hypoactive sexual desire disorder. Medherant’s TEPI patch has been developed to fill this unmet medical need.
Transcenta is employing its unique, cutting-edge discovery technology to develop antibody-based therapies that address unmet medical needs in oncology, immunology and inflammation.
With its innovative VECTrans platform, Vect-Horus is enabling targeted drug delivery across the blood–brain barrier, potentially transforming the treatment of neurodegenerative disorders.
European biotech company Cellis has developed breakthrough platform technology to overcome the limitations of current solid-tumor treatments and provide life-changing therapies for cancer patients, advancing the field of precision oncology.
UK-based DefiniGEN has developed iPSC-derived cell lines that can replace primary human hepatocytes for toxicity testing and accelerate the development of novel liver-targeted therapeutics.
MultiOmic Health is using a data-driven AI-enabled approach to develop tailored therapeutics for specific subpopulations of patients with metabolic syndrome-related conditions, which affect around half of the adult population worldwide.
Canadian biopharma companies are capitalizing on increased government investment stimulated by the recent pandemic to strengthen domestic capabilities and foster multinational partnerships that enhance drug discovery and development worldwide.
Find Therapeutics’ experienced leadership is developing a novel approach to repair myelin damage in multiple sclerosis, often associated with early visual impairment.
BioCanRx is leading the way in the translation, manufacture and adoption of immunotherapies in Canada to ensure that Canadian patients have access to this powerful therapeutic approach via clinical trials.
The Korea Drug Development Fund supports drug development across all areas of medicine, and here present three companies at the forefront of immunology.
